Elisabeth-TweeSteden Ziekenhuis
- Address
- Hilvarenbeekse Weg 60, 5022 Tilburg, The Netherlands
Elisabeth-TweeSteden Ziekenhuis Multiple Sclerosis Research Center
Elisabeth-TweeSteden Ziekenhuis is actively engaged in advancing treatment strategies for patients with relapsing remitting multiple sclerosis (RRMS). The center participates in innovative research focused on optimizing therapeutic regimens to improve patient outcomes while potentially reducing treatment burden and healthcare costs associated with chronic neurological conditions.
- Personalized dosing strategies for disease-modifying therapies in multiple sclerosis
- Extended interval dosing protocols for natalizumab treatment
- Real-world feasibility and safety validation studies in neurological disorders
The research center's participation in the NEXT-MS trial demonstrates its commitment to developing individualized treatment approaches that balance efficacy with patient convenience. By investigating extended dosing intervals starting from 6 weeks for natalizumab therapy, the center contributes to evidence-based optimization of MS management in real-life clinical settings across the Netherlands.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Aalborg University Hospital1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Elisabeth-TweeSteden Ziekenhuis
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Personalized Extended Interval Dosing of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis | Amsterdam UMC Stichting | Phase III | Not Recruiting | Jul 2024 | — |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Adalimumab | 1 | Unknown | 2026-06-09 | 2026-06-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.